Tocilizumab Injection (Subcutaneous Injection).

Effects and efficacy: This product is mainly used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome and other diseases. Usage and dosage: Tocilizumab injection is used for intravenous drip. Medical professionals need to dilute tocilizumab with 0.9% sterile saline to 100ml using aseptic operation methods. Rheumatoid arthritis: The recommended dose for adults is 8mg/kg, intravenous drip once every 4 weeks. When liver enzyme abnormalities, decreased neutrophil counts, and decreased platelet counts occur, the dose of tocilizumab can be reduced to 4mg/kg. It is recommended that the intravenous drip time of tocilizumab be more than 1 hour. For patients with a body weight greater than 100kg, the recommended drip dose each time should not exceed 800mg. Systemic juvenile idiopathic arthritis: If the patient’s body weight is less than 30kg, the generally recommended dose is 12mg/kg, administered once every 2 weeks; if the patient’s body weight is ≥30kg, 8mg/kg, administered once every 2 weeks. It is recommended that the intravenous drip time be more than 1 hour. Cytokine release syndrome: For patients with a body weight of ≥30kg, the recommended dose is 8 mg/kg, and for patients with a body weight of <30kg, the recommended dose is 12 mg/kg. Tocilizumab can be used alone or in combination with corticosteroids. Tocilizumab injection (subcutaneous injection) is administered subcutaneously. The recommended dose for adults is 162 mg once every 2 weeks for the treatment of rheumatoid arthritis. If the patient does not respond adequately, the dose can be adjusted to once a week.
Drug contraindications:
Allergic reactions to this product are contraindicated
Related dosage forms:
Tocilizumab injection